Live Breaking News & Updates on Phase Iii Clinical Trials
Stay updated with breaking news from Phase iii clinical trials. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MENLO PARK, Calif., January 03, 2024 Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 09, 2024, at 1:30 PM PT. Robert W. Duggan, Chairman and Chief Executive Officer, and Dr. Maky Zanganeh, Chief Executive Officer and President, will provide details around the progress of our organization, including updates related to the development of our i ....
Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 2023 Earnings Call Transcript November 7, 2023 Operator: Good morning, and welcome to the Summit Therapeutics Third Quarter 2023 Earnings and Update Call. All participants will be able to listen only until the question-and-answer portion of this call. We do not expect any technical difficulties today; however, in the event […] ....
Japanese trading and pharmaceuticals company Kowa Co Ltd on Monday said that anti-parasite drug ivermectin showed an "antiviral effect" against Omicron and other coronavirus variants in joint non-clinical research. The company, which has been working with Tokyo's Kitasato University on testing the drug as a potential treatment for COVID-19, did not provide further details. The original Reuters story misstated that ivermectin was "effective" against Omicron in Phase III clinical trials, which are conducted in humans. ....
An affiliate of China's state-owned drug maker Sinopharm said on Wednesday its COVID-19 vaccine showed 79.34% efficacy and it has requested regulatory approval of the shot, moving a step closer to become China's first approved vaccine for general public use. The efficacy rate, based on an interim analysis of Phase III clinical trials, is lower than 86% rate for the same vaccine announced by the United Arab Emirates on Dec. 9, based on preliminary data from trials there. There have been fragmentary releases of efficacy data for Chinese vaccine makers' COVID-19 candidates, which are being considered by many developing countries for mass inoculation campaigns. ....